Big Pharma · Rare Disease

Novartis — Rare Disease

• Rare Disease
• Oncology
• Immunology
• Cardiometabolic
• Neurology

Novartis across Rare Disease: Fabhalta, and the 6 AXLRx reports mapping the competitive, patient-flow and payer picture — each scoped to a single asset and cited to a live source.